Legence And 2 Other Stocks That May Be Priced Below Estimated Value

As the U.S. market grapples with rising Treasury yields and uncertainty surrounding Federal Reserve decisions, investors are keenly observing potential opportunities amid recent index declines. In this environment, identifying undervalued stocks can be crucial for those looking to capitalize on discrepancies between market price and estimated value, as these stocks might offer growth potential despite broader economic challenges.

Prediction Market powered by

Top 10 Undervalued Stocks Based On Cash Flows In The United States

Name Current Price Fair Value (Est) Discount (Est) Workiva (WK) $85.72 $167.10 48.7% Valley National Bancorp (VLY) $11.83 $23.11 48.8% UMB Financial (UMBF) $122.07 $243.75 49.9% Seven Hills Realty Trust (SEVN) $9.18 $18.18 49.5% Perfect (PERF) $1.74 $3.43 49.3% Krystal Biotech (KRYS) $285.04 $556.66 48.8% Investar Holding (ISTR) $27.57 $53.60 48.6% Horizon Bancorp (HBNC) $17.51 $34.29 48.9% Gaotu Techedu (GOTU) $2.39 $4.64 48.5% Dime Community Bancshares (DCOM) $30.91 $60.90 49.2%

Click here to see the full list of 179 stocks from our Undervalued US Stocks Based On Cash Flows screener.

Let's explore several standout options from the results in the screener.

Legence

Overview: Legence Corp. offers engineering, installation, and maintenance services for mission-critical systems in buildings across the United States, with a market cap of $5.35 billion.

Operations: The company's revenue is derived from two main segments: Engineering & Consulting, which contributes $710.59 million, and Installation & Maintenance, generating $1.65 billion.

Estimated Discount To Fair Value: 13.1%

Legence Corp. is trading at US$49.59, approximately 13.1% below its estimated fair value of US$57.05, suggesting it may be undervalued based on cash flows. Recent index inclusions and a successful follow-on equity offering of US$378 million enhance its market visibility and capital structure. Despite reporting a net loss for the recent period, Legence's revenue grew by 19.4% year-over-year, with forecasts indicating continued growth exceeding the broader market rate.

Our expertly prepared growth report on Legence implies its future financial outlook may be stronger than recent results. Delve into the full analysis health report here for a deeper understanding of Legence.LGN Discounted Cash Flow as at Jan 2026

Insulet

Overview: Insulet Corporation develops, manufactures, and sells insulin delivery systems for individuals with insulin-dependent diabetes both in the United States and internationally, with a market cap of approximately $20.24 billion.

Operations: The company's revenue primarily comes from its drug delivery systems segment, which generated $2.52 billion.

Story Continues

Estimated Discount To Fair Value: 11.4%

Insulet is trading at US$287.70, 11.4% below its fair value estimate of US$324.80, indicating potential undervaluation based on cash flows. Despite a decline in net profit margin from 21.2% to 9.8%, earnings are expected to grow significantly by over 20% annually, surpassing the broader market's growth rate of 16.1%. Recent FDA clearance for Omnipod 5 enhancements and expanded recycling initiatives further support Insulet's strategic growth trajectory and commitment to innovation.

Upon reviewing our latest growth report, Insulet's projected financial performance appears quite optimistic. Click here to discover the nuances of Insulet with our detailed financial health report.PODD Discounted Cash Flow as at Jan 2026

UMB Financial

Overview: UMB Financial Corporation is a bank holding company offering banking and asset servicing services in the United States and internationally, with a market cap of $9.27 billion.

Operations: The company's revenue is derived from three main segments: Personal Banking ($386.78 million), Commercial Banking ($1.15 billion), and Institutional Banking, including Healthcare Services ($680.53 million).

Estimated Discount To Fair Value: 49.9%

UMB Financial is trading at US$122.07, significantly below its estimated fair value of US$243.75, highlighting undervaluation based on cash flows. Earnings are forecast to grow substantially by 22.3% annually, outpacing the broader U.S. market's growth rate of 16.1%. Despite recent net charge-offs increasing to US$18.38 million from US$8.45 million a year ago, the company maintains steady dividend payouts and reported strong earnings growth in the third quarter of 2025.

Our earnings growth report unveils the potential for significant increases in UMB Financial's future results. Dive into the specifics of UMB Financial here with our thorough financial health report.UMBF Discounted Cash Flow as at Jan 2026

Key Takeaways

Get an in-depth perspective on all 179 Undervalued US Stocks Based On Cash Flows by using our screener here. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance. Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Contemplating Other Strategies?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include LGNPODD and UMBF.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments